{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:57:37Z","timestamp":1789790257523,"version":"4.0.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006345","name":"Uniwersytet Mikolaja Kopernika w Toruniu","doi-asserted-by":"publisher","award":["90-SIDUB.6102.88.2023"],"award-info":[{"award-number":["90-SIDUB.6102.88.2023"]}],"id":[{"id":"10.13039\/501100006345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006345","name":"Uniwersytet Mikolaja Kopernika w Toruniu","doi-asserted-by":"publisher","award":["G4NCUS7"],"award-info":[{"award-number":["G4NCUS7"]}],"id":[{"id":"10.13039\/501100006345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.yexcr.2025.114555","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:38:13Z","timestamp":1744479493000},"page":"114555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Biomarkers for the detection of circulating tumor cells"],"prefix":"10.1016","volume":"448","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-7598","authenticated-orcid":false,"given":"Karol","family":"Gostomczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Drozd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-4534","authenticated-orcid":false,"given":"Mohammed Dheyaa","family":"Marsool Marsool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5102-0103","authenticated-orcid":false,"given":"Anju","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9442-8624","authenticated-orcid":false,"given":"Khachirha","family":"Tugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-2825","authenticated-orcid":false,"given":"Jose","family":"Chacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamnah","family":"Tayyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u0119drzej","family":"Borowczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Szylberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.yexcr.2025.114555_bib1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib2","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.clbc.2023.05.011","article-title":"Association between obesity and circulating tumor cells in early breast cancer patients","volume":"23","author":"Tzschaschel","year":"2023","journal-title":"Clin. Breast Cancer"},{"issue":"3\u20134","key":"10.1016\/j.yexcr.2025.114555_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/03936155231192674","article-title":"Diagnostic value of programmed cell death-ligand 1 expression on circulating tumor cells in lung cancer: a systematic review and meta-analysis","volume":"38","author":"Cui","year":"2023","journal-title":"Int. J. Biol. Markers"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10238-023-01009-0","article-title":"Prognostic value of stem-like circulating tumor cells in patients with cancer: a systematic review and meta-analysis","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-023-11711-7","article-title":"Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors","volume":"23","author":"Ju","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/ALN.0000000000003409","article-title":"Anesthesia and circulating tumor cells in primary breast cancer patients: a randomized controlled trial","volume":"133","author":"Hovaguimian","year":"2020","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/SLA.0000000000005708","article-title":"Persistent circulating tumor cells at 1 Year after oncologic resection predict late recurrence in pancreatic cancer","volume":"277","author":"Javed","year":"2023","journal-title":"Ann. Surg."},{"issue":"22","key":"10.1016\/j.yexcr.2025.114555_bib8","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, A TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","article-title":"Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial","volume":"7","author":"Bidard","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/cells8060516","article-title":"Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer prodige-14 trial","volume":"8","author":"Bidard","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2025.114555_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12916-022-02681-x","article-title":"Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","volume":"20","author":"Shen","year":"2022","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14737159.2021.1910025","article-title":"Values of liquid biopsy in early detection of cancer: results from meta-analysis","volume":"21","author":"Jia","year":"2021","journal-title":"Expert Rev. Mol. Diagn"},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1078-0432.CCR-22-2128","article-title":"Evaluation of a liquid biopsy-breast cancer methylation (LBx-BCM) cartridge assay for predicting early disease progression and survival: TBCRC 005 prospective trial","volume":"29","author":"Visvanathan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.yexcr.2025.114555_bib15","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1002\/cam4.3276","article-title":"Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: a meta-analysis","volume":"9","author":"Zhu","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib16","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1186\/s12885-022-10217-y","volume":"22","author":"Lincoln","year":"2022","journal-title":"BMC Cancer"},{"issue":"1\u20132","key":"10.1016\/j.yexcr.2025.114555_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/carcin\/bgad091","article-title":"Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis","volume":"45","author":"Mohamed","year":"2024","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2025.114555_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1368103","article-title":"Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial","volume":"15","author":"Koeneman","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab066","article-title":"Cancer antigen 15-3\/mucin 1 levels in CCTG MA.32: a breast cancer randomized trial of metformin vs placebo","volume":"5","author":"Goodwin","year":"2021","journal-title":"JNCI Cancer Spectr."},{"issue":"17","key":"10.1016\/j.yexcr.2025.114555_bib20","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELIMination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.yexcr.2025.114555_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","article-title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","volume":"24","author":"\u00d6zg\u00fcro\u011flu","year":"2023","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib22","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.acra.2022.02.024","article-title":"A combination of radiomic features, imaging characteristics, and serum tumor biomarkers to predict the possibility of the high-grade subtypes of lung adenocarcinoma","volume":"29","author":"Liu","year":"2022","journal-title":"Acad. Radiol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-023-01619-2","article-title":"The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy","volume":"25","author":"Wimberger","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7890","key":"10.1016\/j.yexcr.2025.114555_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.yexcr.2025.114555_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303481","article-title":"Attenuating epithelial-to-mesenchymal transition in cancer through angiopoietin-like 4 inhibition in a 3D tumor microenvironment model","volume":"13","author":"Liao","year":"2024","journal-title":"Adv. Healthcare Mater."},{"issue":"11","key":"10.1016\/j.yexcr.2025.114555_bib27","article-title":"Dampened regulatory circuitry of TEAD1\/ITGA1\/ITGA2 promotes TGF\u03b21 signaling to orchestrate prostate cancer progression","volume":"11","author":"Cruz","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"11","key":"10.1016\/j.yexcr.2025.114555_bib28","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.3390\/curroncol29110654","article-title":"PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas","volume":"29","author":"Muralidharan","year":"2022","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib30","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1002\/jcb.27768","article-title":"Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer","volume":"120","author":"Cai","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.yexcr.2025.114555_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202300096","article-title":"Single-cell enzymatic screening for epithelial mesenchymal transition with an ultrasensitive superwetting droplet-array microchip","volume":"7","author":"Xiao","year":"2023","journal-title":"Small Methods"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cac2.12408","article-title":"\u03bc-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR\/AKT\/Slug pathway: a comprehensive study including randomized controlled trial","volume":"43","author":"Wang","year":"2023","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0346-4","article-title":"The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer","volume":"39","author":"Guan","year":"2019","journal-title":"Cancer Commun."},{"issue":"7973","key":"10.1016\/j.yexcr.2025.114555_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41586-023-06367-z","article-title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","volume":"620","author":"Cassier","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jtcvs.2022.10.007","volume":"165","author":"Rusch","year":"2023","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.yexcr.2025.114555_bib36","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.10777","article-title":"Comparison of circulating tumor cell (CTC) detection rates with epithelial cell adhesion molecule (EpCAM) and cell surface vimentin (CSV) antibodies in different solid tumors: a retrospective study","volume":"9","author":"Gao","year":"2021","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/00365521.2022.2106152","article-title":"Synergistic diagnostic value of circulating tumor cells and tumor markers CEA\/CA19-9 in colorectal cancer","volume":"58","author":"Cai","year":"2023","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114555_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/life12020165","article-title":"Predictive value of circulating tumor cells detected by ISET\u00ae in patients with non-metastatic prostate cancer undergoing radical prostatectomy","volume":"12","author":"Garrido Castillo","year":"2022","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12885-024-12139-3","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.yexcr.2025.114555_bib40","article-title":"The analysis of boric acid effect on epithelial-mesenchymal transition of CD133 + CD117 + lung cancer stem cells","volume":"27","author":"Semerci Sevimli","year":"2024","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10544-017-0230-z","article-title":"Microfluidic device for novel breast cancer screening by blood test using miRNA beacon probe","volume":"19","author":"Salim","year":"2017","journal-title":"Biomed. Microdevices"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib42","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/1535-7163.MCT-22-0020","article-title":"External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer","volume":"21","author":"Swami","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033788","article-title":"Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines","volume":"7","author":"Powell","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.yexcr.2025.114555_bib44","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00262-023-03386-7","article-title":"Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer","volume":"72","author":"Yu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexcr.2025.114555_bib45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12967-015-0730-7","article-title":"Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2015","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7150\/ntno.22091","article-title":"Nanotechnology-based strategies for early cancer diagnosis using circulating tumor cells as a liquid biopsy","volume":"2","author":"Huang","year":"2018","journal-title":"Nanotheranostics"},{"issue":"21","key":"10.1016\/j.yexcr.2025.114555_bib47","doi-asserted-by":"crossref","first-page":"34884","DOI":"10.18632\/oncotarget.16818","article-title":"Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients","volume":"8","author":"Togo","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib48","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1021\/acsami.0c20916","article-title":"Tannic acid (TA)-Functionalized magnetic nanoparticles for EpCAM-independent circulating tumor cell (CTC) isolation from patients with different cancers","volume":"13","author":"Ding","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib49","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114555_bib50","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131458","article-title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.yexcr.2025.114555_bib52","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12943-015-0421-2","article-title":"Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells","volume":"14","author":"Alsuliman","year":"2015","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib53","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/1878-0261.12643","article-title":"Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients","volume":"14","author":"Liu","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.yexcr.2025.114555_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.humpath.2016.07.007","article-title":"PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung","volume":"58","author":"Kim","year":"2016","journal-title":"Hum. Pathol."},{"issue":"30","key":"10.1016\/j.yexcr.2025.114555_bib55","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1038\/s41388-018-0252-x","article-title":"Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin \u03b24\/SNAI1\/SIRT3 signaling pathway","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"issue":"5 Pt A","key":"10.1016\/j.yexcr.2025.114555_bib56","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","article-title":"PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation","volume":"1864","author":"Qiu","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib58","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3390\/biomedicines11061768","article-title":"Clinical significance of PD-L1 status in circulating tumor cells for cancer management during immunotherapy","volume":"11","author":"Strati","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cllc.2021.03.005","article-title":"PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"22","author":"Dall'Olio","year":"2021","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"10.1016\/j.yexcr.2025.114555_bib60","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/hep4.1577","article-title":"Hepatocellular carcinoma-circulating tumor cells expressing PD-L1 are prognostic and potentially associated with response to checkpoint inhibitors","volume":"4","author":"Winograd","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"31","key":"10.1016\/j.yexcr.2025.114555_bib61","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.22.00219","article-title":"Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma","volume":"40","author":"Bootsma","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib62","doi-asserted-by":"crossref","first-page":"e2227","DOI":"10.1002\/onco.13981","article-title":"Assessment of PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with cancer receiving PD-1\/PD-L1 blockade therapies","volume":"26","author":"Tan","year":"2021","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib63","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/annonc\/mdx206","article-title":"Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma","volume":"28","author":"Strati","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1759-7714.14767","article-title":"Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.yexcr.2025.114555_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100179","article-title":"Prognostic significance of circulating tumor cell measurement in the peripheral blood of patients with nasopharyngeal carcinoma","volume":"78","author":"Gao","year":"2023","journal-title":"Clinics"},{"issue":"18","key":"10.1016\/j.yexcr.2025.114555_bib66","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3390\/cancers13184619","article-title":"Technical challenges for CTC implementation in breast cancer","volume":"13","author":"Ramos-Medina","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10555-023-10154-7","article-title":"Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance","volume":"43","author":"Tabatabaee","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.yexcr.2025.114555_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2018.03.015","article-title":"DRR1 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via regulating AKT activation","volume":"423","author":"Ma","year":"2018","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib69","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s42003-022-03506-6","article-title":"GPR87 promotes tumor cell invasion and mediates the immunogenomic landscape of lung adenocarcinoma","volume":"5","author":"Bai","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.yexcr.2025.114555_bib70","article-title":"High vimentin expression predicts a poor prognosis and progression in colorectal cancer: a study with meta-analysis and TCGA database","volume":"31","author":"Du","year":"2018","journal-title":"BioMed Res. Int."},{"issue":"13","key":"10.1016\/j.yexcr.2025.114555_bib71","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/nu16132101","article-title":"Intermittent fasting attenuates obesity-induced triple-negative breast cancer progression by disrupting cell cycle, epithelial-mesenchymal transition, immune contexture, and proinflammatory signature","volume":"16","author":"Son","year":"2024","journal-title":"Nutrients"},{"issue":"24","key":"10.1016\/j.yexcr.2025.114555_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417539","article-title":"Shake it up baby now: the changing focus on TWIST1 and epithelial to mesenchymal transition in cancer and other diseases","volume":"24","author":"Mirjat","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114555_bib73","article-title":"Twist-mediated epithelial-mesenchymal transition promotes breast tumor cell invasion via inhibition of Hippo pathway","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2025.114555_bib74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2022.11.002","article-title":"Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy","volume":"87","author":"Wang","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13578-021-00600-w","article-title":"Research models and mesenchymal\/epithelial plasticity of osteosarcoma","volume":"11","author":"Yu","year":"2021","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12964-023-01262-6","article-title":"Roles of Twist1 in lipid and glucose metabolism","volume":"21","author":"Huang","year":"2023","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cam4.4431","article-title":"A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA","volume":"11","author":"Wang","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.yexcr.2025.114555_bib78","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.csbj.2020.09.023","article-title":"TGIF1-Twist1 axis in pancreatic ductal adenocarcinoma","volume":"18","author":"Razzaque","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"17","key":"10.1016\/j.yexcr.2025.114555_bib79","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib80","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/med.21948","article-title":"Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds","volume":"43","author":"Ang","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.yexcr.2025.114555_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","article-title":"Transcriptional regulation of EMT transcription factors in cancer","volume":"97","author":"Saitoh","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.yexcr.2025.114555_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updates"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib83","article-title":"Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells","volume":"1878","author":"Kielbik","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12967-020-02240-z","article-title":"Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer","volume":"18","author":"Wu","year":"2020","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.yexcr.2025.114555_bib85","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jcp.30759","article-title":"NF-\u03baB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition","volume":"237","author":"Mirzaei","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.yexcr.2025.114555_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113490","article-title":"ZEB1: catalyst of immune escape during tumor metastasis","volume":"153","author":"Lu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib87","article-title":"Low PRRX1 expression and high ZEB1 expression are significantly correlated with epithelial-mesenchymal transition and tumor angiogenesis in non-small cell lung cancer","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine (Baltim.)"},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib88","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/hed.26104","article-title":"Prognostic value of epithelial-mesenchymal transition-inducing transcription factors in head and neck squamous cell carcinoma: a meta-analysis","volume":"42","author":"Wan","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.yexcr.2025.114555_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113774","article-title":"EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions","volume":"155","author":"Hashemi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.yexcr.2025.114555_bib90","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2025.114555_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1137013","article-title":"Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment","volume":"11","author":"Lin","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib92","first-page":"1391","article-title":"Cadherins down-regulation: towards a better understanding of their relevance in colorectal cancer","volume":"35","author":"Losi","year":"2020","journal-title":"Histol. Histopathol."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib93","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2021.2005420","article-title":"Dual role of E-cadherin in cancer cells","volume":"10","author":"Rubtsova","year":"2022","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/cells9010027","article-title":"Fibronectin in cancer: friend or foe","volume":"9","author":"Lin","year":"2019","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib95","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jcp.31048","article-title":"Shielding and nurturing: fibronectin as a modulator of cancer drug resistance","volume":"238","author":"Farooq","year":"2023","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.yexcr.2025.114555_bib96","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/10799893.2020.1817074","article-title":"Fibronectin and colorectal cancer: signaling pathways and clinical implications","volume":"41","author":"Wang","year":"2021","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib97","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ijrobp.2020.11.053","article-title":"Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: a phase 1 study","volume":"109","author":"Van Limbergen","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.yexcr.2025.114555_bib98","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2021.03.038","article-title":"Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas","volume":"150","author":"Schliemann","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib99","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biom11121850","article-title":"CD44: a multifunctional mediator of cancer progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"issue":"24","key":"10.1016\/j.yexcr.2025.114555_bib100","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting","volume":"289","author":"Guo","year":"2022","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114555_bib101","first-page":"105","article-title":"Prognostic and clinical value of CD44 and CD133 in esophageal cancer: a systematic review and meta-analysis","volume":"19","author":"Kamil","year":"2020","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"9","key":"10.1016\/j.yexcr.2025.114555_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0291972","article-title":"CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions","volume":"18","author":"Sunny","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1512","article-title":"circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma","volume":"13","author":"Liu","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"5","key":"10.1016\/j.yexcr.2025.114555_bib104","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/jcmm.16296","article-title":"KYNU, a novel potential target that underpins CD44-promoted breast tumour cell invasion","volume":"25","author":"Al-Mansoob","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"21","key":"10.1016\/j.yexcr.2025.114555_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115812","article-title":"The hyaluronan\/CD44 Axis: a double-edged sword in cancer","volume":"24","author":"Cirillo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.yexcr.2025.114555_bib106","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.7150\/ijbs.23586","article-title":"Novel CD44-downstream signaling pathways mediating breast tumor invasion","volume":"14","author":"Ouhtit","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib107","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/1568009618666180706165222","article-title":"Focal adhesion kinase in ovarian cancer: a potential therapeutic target for platinum and taxane-resistant tumors","volume":"19","author":"Levy","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.yexcr.2025.114555_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.883831","article-title":"CD44 glycosylation as a therapeutic target in oncology","volume":"12","author":"Liao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2025.114555_bib109","article-title":"Proteolytic processing of CD44 and its implications in cancer","volume":"2021","author":"Medrano-Gonz\u00e1lez","year":"2021","journal-title":"Stem Cell. Int."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/wound.2020.1192","article-title":"Hyaluronan, transforming growth factor \u03b2, and extra domain A-fibronectin: a fibrotic triad","volume":"10","author":"McKeown-Longo","year":"2021","journal-title":"Adv. Wound Care"},{"issue":"11","key":"10.1016\/j.yexcr.2025.114555_bib111","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.3390\/ijms24119728","article-title":"Co-expression of podoplanin and CD44 in proliferative vitreoretinopathy epiretinal membranes","volume":"24","author":"Bonente","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114555_bib112","article-title":"The roles of hyaluronan in kidney development, physiology and disease","volume":"27","author":"Rabelink","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib113","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/cells10010166","article-title":"MMP-9 signaling pathways that engage rho GTPases in brain plasticity","volume":"10","author":"Figiel","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib114","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1002\/jcp.27740","article-title":"Cancer stem cells (CSCs) in cancer progression and therapy","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3892\/ol.2021.13139","article-title":"Biological function and molecular mechanism of SRSF3 in cancer and beyond","volume":"23","author":"Xiong","year":"2022","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib116","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/1744666X.2019.1561283","article-title":"New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions","volume":"15","author":"Schiano","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib117","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20240493","article-title":"Transglutaminase 2-mediated histone monoaminylation and its role in cancer","volume":"44","author":"Li","year":"2024","journal-title":"Biosci. Rep."},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/cells13080667","article-title":"Biological implications and functional significance of transglutaminase type 2 in nervous system tumors","volume":"13","author":"Buccarelli","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/15548627.2021.1909406","article-title":"How autophagy controls the intestinal epithelial barrier","volume":"18","author":"Foerster","year":"2022","journal-title":"Autophagy"},{"issue":"11","key":"10.1016\/j.yexcr.2025.114555_bib120","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/cells11111779","article-title":"The outside-in journey of tissue transglutaminase in cancer","volume":"11","author":"Sima","year":"2022","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.yexcr.2025.114555_bib121","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.257337","article-title":"The physiology, pathology and potential therapeutic application of serotonylation","volume":"134","author":"Jiang","year":"2021","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.yexcr.2025.114555_bib122","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41419-019-1392-9","article-title":"Defective proteostasis in celiac disease as a new therapeutic target","volume":"10","author":"Maiuri","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2025.114555_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145323","article-title":"Emerging histone glutamine modifications mediated gene expression in cell differentiation and the VTA reward pathway","volume":"768","author":"Patra","year":"2021","journal-title":"Gene"},{"issue":"19","key":"10.1016\/j.yexcr.2025.114555_bib124","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.3390\/cancers14194596","article-title":"The role of RKIP in the regulation of EMT in the tumor microenvironment","volume":"14","author":"Cessna","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.yexcr.2025.114555_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151220","article-title":"Multiple roles for basement membrane proteins in cancer progression and EMT","volume":"101","author":"Banerjee","year":"2022","journal-title":"Eur. J. Cell Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib126","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-019-2058-1","article-title":"The role of collagen in cancer: from bench to bedside","volume":"17","author":"Xu","year":"2019","journal-title":"J. Transl. Med."},{"issue":"17","key":"10.1016\/j.yexcr.2025.114555_bib127","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.3390\/ijms22179185","article-title":"Extracellular matrix biomarkers in colorectal cancer","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114555_bib128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2016.07.004","article-title":"Laminins and cancer stem cells: partners in crime?","volume":"45","author":"Qin","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/cancers14030466","article-title":"AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis","volume":"14","author":"Goyette","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yexcr.2025.114555_bib131","first-page":"67","article-title":"Targeting AXL in NSCLC","volume":"12","author":"Zaman","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.yexcr.2025.114555_bib132","article-title":"AXL as a target in breast cancer therapy","volume":"2020","author":"Colavito","year":"2020","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.yexcr.2025.114555_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104005","article-title":"AXL receptor as an emerging molecular target in colorectal cancer","volume":"29","author":"De Rosa","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.yexcr.2025.114555_bib134","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jcp-2023-209017","article-title":"Gene of the month: GATA3","volume":"76","author":"Qiang","year":"2023","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.yexcr.2025.114555_bib135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.sbi.2021.05.015","article-title":"The estrogen receptor\/GATA3\/FOXA1 transcriptional network: lessons learned from breast cancer","volume":"71","author":"Martin","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.yexcr.2025.114555_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684140","article-title":"Association between estrogen receptors and GATA3 in bladder cancer: a systematic review and meta-analysis of their clinicopathological significance","volume":"12","author":"Bernardo","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.yexcr.2025.114555_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1265520","article-title":"Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib138","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.3390\/ijms24087426","article-title":"The clinical utility of lncRNAs and their application as molecular biomarkers in breast cancer","volume":"24","author":"Arriaga-Canon","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.yexcr.2025.114555_bib139","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","author":"Suzuki-Inoue","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2025.114555_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2023.105841","article-title":"The role of podoplanin inhibitors in controlling oral cancer progression","volume":"157","author":"Sayuddin","year":"2024","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.yexcr.2025.114555_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.807600","article-title":"Platelet CLEC2-podoplanin Axis as a promising target for oral cancer treatment","volume":"12","author":"Hwang","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.yexcr.2025.114555_bib142","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/ijms23031310","article-title":"The role of podoplanin in skin diseases","volume":"23","author":"Asai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2025.114555_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211038142","article-title":"Prognostic value of podoplanin in various tumors","volume":"20","author":"Wang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"Pt 1","key":"10.1016\/j.yexcr.2025.114555_bib144","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","article-title":"SOX2 in development and cancer biology","volume":"67","author":"Novak","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.yexcr.2025.114555_bib145","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41388-021-02157-x","article-title":"SOX2 mediates metabolic reprogramming of prostate cancer cells","volume":"41","author":"de Wet","year":"2022","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.yexcr.2025.114555_bib146","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/0008-5472.CAN-21-0567","article-title":"Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib147","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10717544.2022.2057617","article-title":"Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3\/SOX2 axis","volume":"29","author":"Xie","year":"2022","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib148","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.devcel.2020.10.014","article-title":"Stromal SOX2 upregulation promotes tumorigenesis through the generation of a SFRP1\/2-expressing cancer-associated fibroblast population","volume":"56","author":"Kasashima","year":"2021","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.yexcr.2025.114555_bib149","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/07853890.2022.2056239","article-title":"Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer","volume":"54","author":"Peng","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.yexcr.2025.114555_bib150","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","article-title":"Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies","volume":"11","author":"Walcher","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272500151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448272500151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:17:06Z","timestamp":1778645826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448272500151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S001448272500151X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114555","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers for the detection of circulating tumor cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114555"}}